|
Patients (%)
|
94 (15.3%)
|
520 (84.7%)
|
189 (47.7%)
|
207 (52.3%)
|
283 (28.0%)
|
727 (72.0%)
|
|
Mean age (year)
|
64 (41–84)
|
64 (45–78)
|
69 (45–86)
|
69 (39–88)
|
68 (41–86)
|
65 (39–88)
|
|
Patients with other cancers (%)
|
1 (1.1%)
|
4 (0.8%)
|
2 (1.1%)
|
1 (0.5%)
|
3 (1.1%)
|
5 (0.7%)
|
|
Gleason score (%)
| | | | | | |
|
Group 1: ≤ 6 (≤ 3 + 3)
|
NA
|
124 (23.8%)
|
NA
|
39 (18.8%)
|
NA
|
163 (22.4%)
|
|
Group 2: 7 (3 + 4)
|
NA
|
218 (41.9%)
|
NA
|
54 (26.1%)
|
NA
|
272 (37.4%)
|
|
Group 3: 7 (4 + 3)
|
NA
|
136 (26.2%)
|
NA
|
55 (26.6%)
|
NA
|
191 (26.3%)
|
|
Group 4: 8 (4 + 4, 3 + 5, 5 + 3)
|
NA
|
17 (3.3%)
|
NA
|
30 (14.5%)
|
NA
|
47 (6.5%)
|
|
Group 5: 9 or 10 (4 + 5, 5 + 4, or 5 + 5)
|
NA
|
25 (4.8%)
|
NA
|
29 (14.0%)
|
NA
|
54 (7.4%)
|
|
Mean PSA (ng/mL)
|
10.1
|
6.1
|
10.6
|
67.9
|
10.51
|
65.0
|
